Welcome to our dedicated page for Privia Health Group news (Ticker: PRVA), a resource for investors and traders seeking the latest updates and insights on Privia Health Group stock.
Privia Health Group operates as a U.S. physician enablement company focused on primary-care centric medical groups, risk-bearing entities and the Privia Platform of technology and service solutions. The company works with medical groups, health plans and health systems to build provider networks and support value-based care.
Company updates commonly cover quarterly and annual operating results, guidance, practice collections, care margin, platform contribution, adjusted EBITDA and provider growth. Recurring developments also include performance in value-based risk arrangements, expansion into new or existing states, material agreements, capital-structure disclosures and governance matters.
Privia Health (Nasdaq: PRVA) reported 1Q 2026 results for the period ended March 31, 2026, with revenue of $603.8M (up 25.8% YoY) and adjusted EBITDA of $36.7M (up 36.3% YoY). Practice collections were $914.8M (+14.6%) and attributed lives rose to 1,606,000.
The company reiterated full‑year 2026 guidance and raised its attributed lives range to 1.600M–1.625M, while GAAP net income was $3.1M and included $21.9M of stock‑based compensation.
Privia Health (Nasdaq: PRVA) will report results for the quarter ended March 31, 2026 before market open on Thursday, May 7, 2026. The release is expected by 7:00 AM ET, with a management conference call at 8:00 AM ET the same day.
Investors can access a live webcast or on-demand replay at ir.priviahealth.com. To join the live call, dial 888-596-4144 (domestic) or 646-968-2525 (international) and use Conference ID 5704885.
Privia Health (Nasdaq: PRVA) earned the 2026 HFMA MAP Award for High Performance in Revenue Cycle, marking recognition in nine of the last ten years. The award reflects sustained excellence across MAP Keys® metrics such as net collection rate, AR performance, denial prevention, and cost to collect.
Privia’s multi-year transformation—analytics, AI automation, provider engagement, and scalable operating models—drove strong MAP benchmark results and the national award presented March 18 at the HFMA Revenue Cycle Conference.
Privia Health (NASDAQ:PRVA), Amalgam Rx, and Exact Sciences (NASDAQ:EXAS) report a Privia-led colorectal cancer screening program that reached an 84% screening rate in 2024, above the 80% national goal. The EHR-integrated, automated outreach program engaged >42,000 patients (scaled to >100,000), processed ~23,000 orders within 48 hours, and found a 10% positivity rate identifying >550 patients needing follow-up.
The program used Cologuard as a noninvasive first-line option and embedded ordering, results, and follow-up into athenaClinicals to support value-based care and eCQM readiness.
Privia Health (Nasdaq: PRVA) reported full-year 2025 results with all operating and financial metrics at or above the high end of guidance. Total revenue was $2,122.8M (+22.3%), Adjusted EBITDA $125.5M (+38.8%), and net income $22.9M (+59.3%).
Year-end cash was $479.7M with no debt; 2025 operating cash flow was $163.4M (+49.5%). 2026 guidance targets ~20% Adjusted EBITDA growth at midpoint and expects ~80% conversion of Adjusted EBITDA to free cash flow.
Privia Health (Nasdaq: PRVA) expects to release financial results for the fourth quarter and full year ended December 31, 2025 before market open on Thursday, February 26, 2026. The release is expected to be publicly available by 7:00 AM ET and on the company's investor relations website. Management will host a conference call and live webcast to discuss results and outlook beginning at 8:00 AM ET the same day; the webcast will be archived for on-demand replay. To join the live call, dial 888-596-4144 (or 646-968-2525 internationally) and use Conference ID 5704885.
Privia Health (Nasdaq: PRVA) reported strong Q3 2025 results on November 6, 2025: total revenue $580.4M (+32.5% YoY), net income $6.9M (+94.1% YoY) and Adjusted EBITDA $38.2M (+61.6% YoY). Practice Collections rose to $940.4M (+27.1%) and Implemented Providers reached 5,250 (+13.1%).
The company signed a definitive agreement to acquire an ACO business from Evolent for $100M cash plus up to $13M earnout, expected to close in Q4 2025 and expand VBC attributed lives above 1.5M. Cash was $441.4M and no debt at 9/30/25; pro forma cash expected ≈$409.9M after pro forma items. FY'25 guidance was raised above prior high end across key metrics.
Privia Health (Nasdaq: PRVA) said it will report third-quarter and nine-month 2025 financial results before market open on Thursday, November 6, 2025. The press release is expected to be publicly available by 7:00 AM ET on the company's Investor Relations site at ir.priviahealth.com. Management will host a conference call and live webcast at 8:00 AM ET on November 6, 2025 to discuss results and outlook; the webcast will be archived for on-demand replay. Dial-in details for the live call are 888-596-4144 (US) or 646-968-2525 (international) with Conference ID 5704885.
Privia Health (Nasdaq: PRVA) has announced a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health (NYSE: EVH) for $100 million in cash, with an additional performance-based payment of up to $13 million.
The acquisition will add over 120,000 attributed lives through Medicare Shared Savings Program (MSSP), commercial, and Medicare Advantage programs, bringing Privia's total attributed lives in value-based care arrangements to 1.5 million across multiple programs. The deal, expected to close in Q4 2025, will be financed with cash on hand and is projected to contribute positively to Adjusted EBITDA in 2026.
Evolent Health (NYSE: EVH) has announced the sale of its value-based primary care business, Evolent Care Partners (ECP), to Privia Health Group for up to $113 million in cash. The transaction includes $100 million at closing and additional payments in Fall 2026 based on MSSP performance.
The strategic divestiture involves ECP's operations serving over 120,000 members through partnerships with 1,000+ physicians in the Medicare Shared Savings Program. The company plans to use proceeds to prepay senior term debt, expecting to improve annual cash flow by over $7 million.
Evolent reaffirmed its Q3 2025 guidance with revenue of $460-480 million and Adjusted EBITDA of $34-42 million, as well as full-year 2025 outlook of $1.85-1.88 billion in revenue and $140-165 million in Adjusted EBITDA, before accounting for the transaction impact.